SAGE Therapeutics' (SAGE) SAGE-547 Phase 2 Met Primary Endpoint in Severe Postpartum Depression - StreetInsider.com

SAGE Therapeutics' (SAGE) SAGE-547 Phase 2 Met Primary Endpoint in Severe Postpartum Depression StreetInsider.com Get the Pulse of the Market with StreetInsider.com's Pulse Picks. Get your Free Trial here. Sage Therapeutics (Nasdaq: SAGE) announced positive top-line results from its Phase 2 clinical trial of SAGE-547 for the treatment of severe postpartum ... Sage Therapeutics' postpartum depression drug succeeds in studyReuters all 3 news articles »

from Health - Google News http://news.google.com/news/url?sa=t&fd=R&ct2=us&usg=AFQjCNFgVQVpM_Gv551UKYiF1ECqCkQJMg&clid=c3a7d30bb8a4878e06b80cf16b898331&cid=52779156634079&ei=m9mEV_jDBs2P3QH176-ABg&url=http://www.streetinsider.com/Corporate%2BNews/SAGE%2BTherapeutics%2B(SAGE)%2BSAGE-547%2BPhase%2B2%2BMet%2BPrimary%2BEndpoint%2Bin%2BSevere%2BPostpartum%2BDepression/11821372.html
via IFTTT